Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ALERS.PA
- Price
- 25.40
- Stock movement down
- -0.05 (-0.20%)
- Company name
- Eurobio Scientific SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Medical Devices
- Markedsværdi
- 254.68M
- Ent værdi
- 344.50M
- Pris/omsætning
- 1.02
- Pris/bog
- 1.42
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- 10.63
- Fremtidig P/E
- 22.88
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- 77.62%
- 3 års afkast
- 3.91%
- 5 års afkast
- 20.02%
- 10 års afkast
- 7.32%
Senest opdateret: 2025-06-22
UDBYTTE
ALERS.PA betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | 10.63 |
| Pris til OCF | 5.13 |
| Pris til FCF | 6.03 |
| Pris til EBITDA | 4.50 |
| EV i forhold til EBITDA | 6.09 |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 1.02 |
| Pris til egenkapital | 1.42 |
| EV i forhold til salg | 1.38 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 10.03M |
| EPS (TTM) | 2.39 |
| FCF pr. aktie (TTM) | 4.21 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 250.22M |
| Bruttofortjeneste (TTM) | 113.40M |
| Driftsindkomst (TTM) | 34.50M |
| Nettoindkomst (TTM) | 23.97M |
| EPS (TTM) | 2.39 |
| EPS (1 år frem) | 1.11 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 45.32% |
| Driftsmargin (TTM) | 13.79% |
| Fortjenstmargin (TTM) | 9.58% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 45.12M |
| Nettotilgodehavender | 27.82M |
| Omsætningsaktiver i alt | 146.67M |
| Goodwill | 117.70M |
| Immaterielle aktiver | 1.95M |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 313.77M |
| Kreditor | 19.12M |
| Kortfristet/nuværende langsigtet gæld | 93.40M |
| Summen af kortfristede forpligtelser | 54.55M |
| Sum gæld | 134.94M |
| Aktionærernes egenkapital | 178.82M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | 49.60M |
| Investeringsudgifter (TTM) | 6.24M |
| Fri pengestrøm (TTM) | 42.25M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | 13.40% |
| Afkast af aktiver | 7.64% |
| Afkast af investeret kapital | 12.34% |
| Kontant afkast af investeret kapital | 21.75% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 25.40 |
| Daglig høj | 25.40 |
| Daglig lav | 25.40 |
| Daglig volumen | 0K |
| Højeste gennem alle tider | 435.35 |
| 1 års analytiker estimat | 30.00 |
| Beta | -0.27 |
| EPS (TTM) | 2.39 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 29 Jul 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ALERS.PA | S&P500 | |
| Nuværende prisfald fra top notering | -94.17% | -3.04% |
| Højeste prisfald | -99.32% | -56.47% |
| Højeste efterår dato | 24 Dec 2018 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -90.99% | -11.04% |
| Gennemsnitlig tid til nyt højdepunkt | 455 days | 12 days |
| Maks. tid til nyt højdepunkt | 4915 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
254.68M
Markedsværdi kategori
Small-cap
Beskrivelse
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and cancer. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, a molecular test for the surveillance of heart-transplant patients; cell culture media, molecular biology reagents, and proprietary antibodies; TQS (Tetanus Quick Stick) for the evaluation of patients' immune status against tetanus; and EBX molecular biology family, which includes a range of tests for identifying various pathogens responsible for infectious diseases and assessing the magnitude of the infection. The company also develops other diagnostic products using molecular biology. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, France.
Personale
329
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
France
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy Paris, July 1st, 2025 Eurobio Scientific (FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PM...
1. juli 2025
EB Development rises above 90% threshold Paris, May 19, 2024 – 7:00 pm - Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life sci...
19. maj 2025
2024 ANNUAL RESULTS Growth of core business and strategic execution Revenue up 19% to €154 million Organic growth at +9%Proprietary products account for a stable 31% of group revenueInternational acco...
28. april 2025
Amidst escalating trade tensions and fluctuating consumer sentiment, the European market has experienced a turbulent period, with the pan-European STOXX Europe 600 Index ending 1.92% lower before rebo...
16. april 2025
Amidst a backdrop of uncertainty in the European markets, with the pan-European STOXX Europe 600 Index recently declining by 1.23% due to concerns over U.S. trade tariffs and monetary policy, investor...
18. marts 2025
EUROBIO SCIENTIFIC INCREASES ITS FOOTPRINT IN ITALY Signing of the acquisition of Life Science unit of Voden Medical Instruments SpaCompletion of the acquisition of Quimark SRLDecision of supplier T2 ...
12. marts 2025
Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners Paris, 1...
19. december 2024
As global markets react to the recent U.S. Federal Reserve rate cut, European indices have shown mixed results, with France's CAC 40 Index posting modest gains. Amid this evolving economic landscape, ...
26. september 2024
RESULTS FOR THE 1ST HALF OF 2024 Revenues up 12% on a like-for-like basis (24% overall)Stable adjusted EBITDA1 and operating profitNet financial debt down slightly to €1.6m, with cash of €86.6mPropose...
24. september 2024
As the European Central Bank's recent rate cut aims to bolster economic growth, France's CAC 40 Index has seen a notable uptick, reflecting positive sentiment in the broader market. In this context of...
19. september 2024
Næste side